Mental Health & Psychiatry Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

This Phase 3 study is exploring the long-term safety of KarXT, an oral medication, for people experiencing psychosis linked to Alzheimer's disease. For patients and caregivers, this research offers hope for a new treatment that may be easier to tolerate and safer over time. The study includes participants worldwide who previously took part in earlier KarXT trials, aiming to provide ongoing support for managing challenging symptoms.

Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities

This Phase 4 trial is testing how well intravenous esketamine and crisis response planning work to prevent suicide in adolescents and adults with recent suicidal thoughts or attempts. If successful, it could bring faster-acting options to reduce suicide risk and improve mental health care. Conducted in Brazil, the study will follow participants for one year to see how safe and effective these approaches are in real-life settings.

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

This global Phase 3 trial is evaluating KarXT as a treatment for psychosis in people aged 55 to 90 with Alzheimer's disease. The goal is to find a new way to manage hallucinations and delusions that come with this condition. Positive results could mean more choices and better symptom control for patients and families dealing with Alzheimer's-related psychosis.

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

This Phase 3 trial is testing KarXT to help prevent the return of psychosis symptoms in adults with Alzheimer's disease. Recruiting in several countries including the United States, it focuses on improving quality of life by reducing episodes of hallucinations and delusions. For patients, this could translate into more stable mental health and less disruption from psychosis.

Ketamine Treatment of Youth Suicide Attempters

This Phase 3 study is investigating ketamine as a treatment for young people aged 14 to 30 who have recently attempted suicide. By combining medication with weekly therapy, the trial aims to offer a quicker way to lower suicide risk and support recovery. If effective, it could provide an important new option for youth suicide prevention in the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.